Hodgkin lymphoma: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers

  NCT05337735· M.D. Anderson Cancer Center· Updated 13 Oct 2026

  “PI Request”Registry text, quoted unchanged. Source

• Suspended

  ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

  NCT06680661· Leland Metheny· Updated 10 Sept 2026

  “insufficient funding”Registry text, quoted unchanged. Source

• Terminated

  Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)

  NCT03598608· Merck Sharp & Dohme LLC· Updated 28 Jul 2026

  “Business Reason”Registry text, quoted unchanged. Source

• Suspended

  Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

  NCT05400122· David Wald· Updated 14 Jul 2026

  “Drugs unavailable”Registry text, quoted unchanged. Source

• Terminated

  Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma

  NCT04788043· Ranjana Advani· Updated 30 Jun 2026

  “Discontinuation of magrolimab development”Registry text, quoted unchanged. Source

• Terminated

  Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis

  NCT04758650· Universitair Ziekenhuis Brussel· Updated 1 Jun 2026

  “Delay in recruitment”Registry text, quoted unchanged. Source

• Terminated

  Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

  NCT03246906· Fred Hutchinson Cancer Center· Updated 14 May 2026

  “Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and Data Safety Monitoring Board recommendations.”Registry text, quoted unchanged. Source

• Terminated

  A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1)

  NCT06761586· Aurigene Discovery Technologies Limited· Updated 17 Apr 2026

  “Patient recruitment problems”Registry text, quoted unchanged. Source

• Terminated

  First in Human, Dose Escalation, Dose Expansion Study of AUR105

  NCT05605119· Aurigene Discovery Technologies Limited· Updated 17 Apr 2026

  “Patient recruitment problems.”Registry text, quoted unchanged. Source

• Terminated

  Impact of Respiratory Training in Lymphoma Survivors

  NCT05938127· University of Colorado, Denver· Updated 27 Feb 2026

  “Low Accrual”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• An early study to investigate a new medicine for Subjects with Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

  NCT03930953· Celgene Corp.· Source

• Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

  NCT02682667· National Cancer Institute (NCI)· Source

• Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

  NCT03407144· Merck Sharp & Dohme LLC· Source

• A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

  NCT06788509· Janssen Research & Development, LLC· Source

• A Long-term Extension Study of PCI-32765 (Ibrutinib)

  NCT01804686· Janssen Research & Development, LLC· Source

• A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

  NCT07519772· Merck Sharp & Dohme LLC· Source

• A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

  NCT04875195· Merck Sharp & Dohme LLC· Source

• Tissue Collection for Studies of Lymph Cancer

  NCT01676805· National Cancer Institute (NCI)· Source

• Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

  NCT03907488· National Cancer Institute (NCI)· Source

• Biology Studies of Hematologic Cancers

  NCT00923442· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 5
• Mendelian Randomization Analysis 6
• CRISPR-Cas Systems 1
• Gene Expression Profiling 14
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 5
• Metabolomics 1
• Flow Cytometry 9
• Immunohistochemistry 19
• Liquid Biopsy 1
• Circulating Tumor DNA 6
• Xenograft Model Antitumor Assays 20
• Positron-Emission Tomography 21
• Magnetic Resonance Imaging 18
• Machine Learning 11
• Deep Learning 3
• Cohort Studies 30
• Genome-Wide Association Study 7

See which targets of this disease your abstract mentions, and go to the people working on them.